title: [Therapy resistance antiphosholipid syndrome in the course of systemic lupus erythematosus: case report].
abstract: Antiphospholipid syndrome (APS) is one of the most common reasons of thromboembolic complications in the course of connective tissue diseases. There is a strong relationship between presence of antiphospholipid antibodies and the risk of thrombosis. APS related thromboembolic complications range from superficial vein thrombosis up to rapidly developing, life threatening, multi-organ embolism. We present a case of a 21-year old female who presented with myocardial infarction as the first symptom of systemic lupus erythematosus and APS. Afterwards she was consequently treated with antithrombotic and anti-aggregation agents but it did not prevent her from reoccurrence of middle retinal vein. During the 10-year follow up she presented with reoccurring neurological symptoms i.e.: headache, memory deficits, concentration loss and impairment of the cognitive functions. She was found many times to be positive for IgG and IgM anticardiolipin antibodies, anti-beta2glicoprotein-I antibodies and lupus anticoagulant.
authors.affiliation: Klinika Reumatologii, Pomorska Akademia Medyczna, Szczecin. danutabs@sci.pam.szczecin.pl
authors.forename: Danuta
authors.initials: D
authors.lastname: Bobrowska-Snarska
authors.forename: Lidia
authors.initials: L
authors.lastname: Ostanek
authors.forename: Beata
authors.initials: B
authors.lastname: Trzcińska-Butkiewicz
authors.forename: Marek
authors.initials: M
authors.lastname: Brzosko
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy*; D018450:Disease Progression; D004351:Drug Resistance; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy*; D055502:Secondary Prevention; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology*; D053482:beta 2-Glycoprotein I / Q000097:blood
chemical_list: D017153:Antibodies, Anticardiolipin; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D053482:beta 2-Glycoprotein I